Profound thrombocytopenia after using Abciximab for no-reflow during primary percutaneous coronary intervention for ST elevation myocardial infarction
분야
의약학 > 내과학
저자
( Soon Young Park ) , ( Jeong Eun Kim ) , ( Sang Min Kim ) , ( Sang Yeub Lee ) , ( Kyung Kuk Hwang ) , ( Dong Woon Kim ) , ( Myeong Chan Cho ) , ( Jang Whan Bae )
발행기관
대한내과학회
간행물정보
대한내과학회 추계학술발표논문집 2011년, 제2011권 제1호, 163(총1쪽)
파일형식
42846476.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    No-reflow phenomenon occurs frequently during primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) and it has a strong negative impact on clinical outcome. Adenosine and verapamil are indicated by ESC guidelines and Abciximab could be also considered for treatment of no-reflow. Complications associated with Abciximab include bleeding and profound thrombocytopenia. This report describes a 65 year-old man with STEMI who had a rare complication of profound thrombocytopenia after using abciximab and Intra-aortic balloon pump (IABP) for treatment of no-reflow with cardiogenic shock during PPCI. After transfusion of platelet concentration, platelet count was improved without thrombotic complication in spite of no-reflow phenomenon and the weaning of IABP could be done safely without bleeding using closing device.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.